SINGAPORE, April 15, 2026 /PRNewswire/ — NLCS (Singapore) was excited to host its first-ever International Model United Nations (MUN) Conference at the end of February, welcoming students from across the NLCS family of schools, including London, Jeju, Dubai and Kobe. The three-day event brought together young delegates for an immersive experience in diplomatic discourse and global problem-solving.

Exploring the theme of ‘Bridges Across Borders’, the conference challenged students to tackle pressing global issues spanning sustainability and human rights, alongside historic crises including the Berlin Airlift of 1948. Across multiple committee sessions, students represented nations from around the world, negotiating complex resolutions from diverse geopolitical perspectives, gaining a deeper understanding of international relations and diverse perspectives.

Bridges Across Borders: Sustainability, Human Rights, and History 

Chris van Dort, Director of MUN at NLCS Singapore, shared: “It is a genuine privilege to host this event for the first time and welcome schools from across multiple continents. Within the NLCS community, these events emphasise our collective vision of raising awareness for global issues whilst acting as global citizens. Running a conference for the first time has been no small task, and it would not have gone as smoothly without the tireless enthusiasm of our excellent students.”

Student-Led Preparation Drives Conference Success 

A significant feature of the conference has been the remarkable level of student leadership involved in its preparation. Much of the planning, training and coordination has been driven by students themselves, with experienced members of the school’s MUN co-curricular activity guiding newer participants on effective debate techniques, research strategies and the art of crafting well-structured resolutions. This peer-led approach has not only strengthened the quality of debate during the conference but also reflects the spirit of MUN itself, a platform where students learn to lead, support one another, and take meaningful ownership of their learning.

One of NLCS (Singapore)’s students delegates mentioned, “Joining NLCS (Singapore) in its founding year made helping organise NLCSIMUN and chairing a committee especially meaningful. I felt immense pride hosting an event reflecting our school’s international culture and academic ambition. Welcoming delegates from sister schools was genuinely exciting – their diverse perspectives made discussions dynamic and insightful. Chairing required vision, adaptability and compassion, deepening my understanding of what MUN truly stands for.”

Student Chairs Guide Debates and Build Community 

During the conference itself, this student leadership takes center stage. These student chairs act as subject matter experts in their respective committees, skillfully guiding debates while creating an inclusive environment where even first-time delegates feel empowered to contribute. They also take on a key role in ensuring that guidelines are followed across the weekend. It’s this combination of responsibility and support that makes MUN such a powerful learning experience, pushing students to lead while simultaneously helping others find their footing.

A committee chair from NLCS London reflected, “Chairing the DISEC committee at NLCSMUN was incredibly rewarding. I was particularly impressed by delegates’ enthusiasm and the high level of debate and diplomacy. It was especially fulfilling to see individuals grow in confidence and flourish throughout the conference. The experience truly embodied the theme of ‘Bridges Across Borders’ and I wished the trip to Singapore could have been longer.”

Beyond the committee rooms, the conference offers rich opportunities for cultural exchange and connection. Visiting delegates also had the opportunity to explore Singapore together, visiting iconic landmarks while building connections with peers from across the NLCS global network. These shared moments culminate in a celebratory gala dinner, bringing all four schools together for an evening that honors not just their accomplishments, but the genuine friendships and mutual respect that have blossomed throughout the event. On the final day of the conference, students also had the opportunity to visit both Gardens by the Bay and the Art Science museum, getting the chance to explore cultural sites together and build fantastic memories.

Cultural Exchange Beyond the Committee Rooms 

For many students, participating in MUN is a transformative experience that encourages them to think beyond their immediate environment and engage thoughtfully with global challenges. They discover their own voices, learn to articulate complex ideas with clarity, and advocate persuasively for positions they may not have considered before. This process of intellectual challenge and personal growth helps them develop empathy, resilience, and the confidence to engage with difficult questions, exemplifying NLCS’s steadfast commitment to developing globally minded citizens equipped with critical thinking, diplomacy, and collaborative problem-solving skills needed to navigate an increasingly interconnected world.

Ultimately, they learn that effective leadership isn’t about having all the answers, it’s about asking the right questions, valuing diverse perspectives, and working together toward solutions that serve the greater good

Developing Global Citizens Through MUN 

Students from NLCS Kobe reflected on their experience, noting “It made me realise that if I work hard, I can do really well and that motivated me to be better. I liked how everyone was friendly and supportive and even picked up a few new English vocabulary and phrases, which inspired me to learn more.”

The inaugural International MUN Conference at NLCS (Singapore) has set a powerful precedent for what the NLCS global network can achieve when students are given the platform to lead. Over three remarkable days, delegates from London, Jeju, Dubai, and Kobe did not just debate resolutions – they built lasting connections, challenged their own perspectives, and demonstrated the kind of thoughtful, collaborative leadership the world needs. In creating this space for student voice and international collaboration, NLCS (Singapore) has shown that when young people are empowered to engage meaningfully with global challenges, they don’t just rise to the occasion, they inspire others to do the same.

About North London Collegiate School (Singapore)     

Founded in August 2020, North London Collegiate School (Singapore) is a British International School offering the academically ambitious NLCS curriculum, followed by the International Baccalaureate (IB) Middle Years Programme and culminating in the IB Diploma Programme.    

Drawing on 175 years of educational heritage from its founding school in the UK, NLCS (Singapore) nurtures individuals to be intellectually curious, socially confident, and grounded in compassion through a rigorous academic framework, rich co-curricular opportunities, and exceptional pastoral care.

Situated on Depot Road, the School is part of a global family of schools committed to educational excellence and developing global citizens.   

To learn more about NLCS (Singapore), please visit our website (https://nlcssingapore.sg/) and follow us on Instagram, Facebook, YouTube, and LinkedIn.   

The move underscores Addepar’s continued global expansion and long-term strategic investment in the region

SINGAPORE, April 14, 2026 /PRNewswire/ — Addepar, a global data and AI platform for investment professionals, today announced the opening of its Singapore office, establishing the city-state as its Asia-Pacific (APAC) hub and reinforcing the company’s long-term commitment to the region.

Located in Singapore’s financial and technology district at Marina Bay Financial Centre, the new office enables the company to deepen client support, expand its regional footprint, and continue building products tailored to the needs of APAC investment professionals. It also reinforces Addepar’s confidence in Singapore as a central hub for its APAC operations, bringing research and development and go-to-market teams closer to clients.

Addepar has supported clients across APAC since 2019, with its regional client base growing over 130% in the past two years. The new office formalises its presence and supports the company’s continued expansion across key wealth markets.

“Singapore is a leading global financial centre and a gateway to Asia-Pacific’s fast-growing investment ecosystem, with a strong focus on innovation and talent,” said Eric Poirier, Chief Executive Officer of Addepar. “Establishing our APAC hub here reflects our commitment to the region and positions us to better deliver the global infrastructure and data-driven insights investment professionals need to operate at scale and make more informed decisions.”

The expansion builds on a foundation of longstanding local partnerships. EDBI, arm of SG Growth Capital, the investment platform of EDB and Enterprise Singapore, invested in Addepar’s 2025 Series G financing round, reflecting shared conviction in Addepar’s global strategy.

“We are pleased to support Addepar as it establishes its Asia-Pacific hub in Singapore, including a Centre of Excellence and product engineering capabilities. This furthers Singapore’s standing as a trusted base for innovation in wealth and asset management, and we see strong opportunities for Addepar to contribute to the growth of Singapore’s financial ecosystem,” said Charmaine Kng, Partner at EDBI.

Today, more than 1,400 firms in approximately 60 countries use Addepar to manage and advise on US$9 trillion in assets. The new Singapore hub further strengthens Addepar’s ability to serve clients across North America, Latin America, Europe, the Middle East and Asia-Pacific — enabling investment professionals worldwide to make decisions with greater clarity and confidence.

About Addepar
Addepar is a global data and AI platform empowering investment professionals to turn complex financial information into actionable intelligence. Addepar unifies portfolio, market and client data in a total portfolio view and delivers AI-powered insights within investment and client workflows. More than 1,400 firms in 60 countries use Addepar to manage and advise on $9 trillion in assets. Its open platform integrates with nearly 650 software, data and consulting partners to power end-to-end investment operations across firms of all sizes and complexity. Addepar supports clients worldwide with offices in New York City, Salt Lake City, London, Edinburgh, Pune, Dubai, Geneva, São Paulo and Singapore.

About SG Growth Capital
SG Growth Capital is the strategic investment platform of the Singapore Economic Development Board (EDB) and Enterprise Singapore. Through our investment arms, EDBI and SEEDS, we support global leaders and local startups to drive innovation from Singapore.

SYDNEY, April 15, 2026 /PRNewswire/ — Nexon Asia Pacific (Nexon), today announced it has become a member of the Microsoft Intelligent Security Association (MISA), an ecosystem of software development companies and security services partners that have integrated their solutions with Microsoft Security technology to better defend our mutual customers against a world of increasing cyber threats.

Nexon supports organisations to strengthen their cyber resilience by combining deep domain expertise with Microsoft’s advanced security technologies, including Microsoft Sentinel, Microsoft Entra ID, Microsoft Purview and Microsoft Defender. The company focuses on delivering clear, reliable outcomes across threat protection, identity security, and compliance, enabling clients to operate with confidence in a constantly evolving risk environment.

Nexon’s subscription‑based Nexon Cyber service plans provide defined service delivery, agreed service levels, and measurable outcomes. This ensures that core protection across even the most complex environments is maintained through a consistent baseline of visibility and defense.

Nexon’s admission to the Microsoft Intelligent Security Association reflects the quality and consistency of the work its security teams deliver every day. It reinforces that Nexon’s solutions align with Microsoft’s highest standards and that its security services integrate seamlessly with the technologies clients rely on. This recognition strengthens the trust placed in Nexon and validates the expertise behind the protection it provides.

“Being welcomed into MISA is a meaningful milestone for Nexon. It reflects the care, consistency, and integrity our teams bring to every security engagement,” said Saba Maroun, Chief Customer Services Officer at Nexon Asia Pacific. “For our clients, this membership provides reassurance that the services we deliver are grounded in deep expertise and validated by Microsoft. Security and trust sit at the centre of everything we do, and this recognition strengthens our commitment to supporting organisations with solutions they can depend on.”

“The Microsoft Intelligent Security Association has grown into a vibrant ecosystem comprised of the most reliable and trusted security vendors across the globe,” said Maria Thomson, Director, Microsoft Intelligent Security Association. “Our members, like Nexon, share Microsoft’s commitment to collaboration within the cybersecurity community to improve our customers’ ability to predict, detect, and respond to security threats faster.”

Established in 2018 to bring together Microsoft leaders, & security vendors, MISA focuses on collaborating to combat security threats and create a safer environment for all. Its mission is to provide intelligent, industry-leading security solutions that work together to help protect organizations at the speed and scale of AI in an ever-increasing threat landscape.

Partners who are interested in learning more can visit the MISA Website: Microsoft Intelligent Security Association.

About Nexon Asia Pacific:

Nexon Asia Pacific (Nexon) is an award-winning digital & IT services partner for mid-market, enterprise & government organisations across Australia.  We have a uniquely broad suite of solutions to service clients who require end-to-end capabilities coupled with specialist expertise in security, cloud, and digital solutions.

Our end-to-end solutions help clients to solve problems, address frictions, and accelerate growth. Committed to the highest standards of responsiveness, competency, and transparency, Nexon is built on a unique client care model that is fueled by continuous feedback. With 600+ staff, we employ some of the country’s most experienced consultants and empower teams to make decisions that accelerate change for client organisations.

As a certified and accredited local and state government provider, CREST, and ISO-certified, Nexon partners with world-class technology vendors to deliver innovative solutions and service excellence.

We help our clients move from a position of being overwhelmed to empowerment, looking forward to a more agile and digital future.

nexon.com.au

Product or service names mentioned herein may be the trademarks of their respective owners.

• 30-50% of costs for heavy industry come from energy consumption
• 25-45% reduction in energy use across aluminium, aviation, cement, plastics & chemicals, shipping and steel is achievable through energy productivity measures including longer product lifetimes and higher recycling rates 
• A c.40%-60% reduction in “green premiums” for aviation and shipping is possible by combining energy productivity with decarbonisation

LONDON, April 15, 2026 /PRNewswire/ — Improving energy productivity can meet rising needs for housing, mobility and goods while reducing reliance on expensive fossil fuels and the need for new energy infrastructure, says a new report from the Energy Transitions Commission (ETC) and Mission Possible Partnership (MPP) published today.

Energy productivity measures the economic value generated from each unit of energy – improving it delivers the same (or greater) output from less energy. The report shows that more efficient ships, planes and industrial plants, using less material, using things for longer and recycling more can reduce the cost and complexity of decarbonising energy-intensive industries while strengthening industrial competitiveness. 

Energy-intensive sectors, aluminium, aviation, cement, plastics & chemicals, shipping and steel, form the foundations of modern economies: our houses, transport and goods. Together, these sectors account for around a quarter of global energy demand.

By 2025, steel, aluminium, cement and plastics & chemicals demand is expected to grow 25%-100%, aviation 150%, and shipping 45%, driven by rising global prosperity, urbanisation and industrialisation. This growth could be delivered using 25-45% less energy and at lower cost, by improving energy productivity, compared to a scenario with no productivity gains, says the new briefing Harnessing energy productivity for industrial competitiveness.  

Three complementary strategies can reduce energy demand across energy-intensive sectors:

1. Technical efficiency – reducing the kWh input required to deliver the same product or service.

2. Service efficiency – reducing the volume of product or service required to deliver the same standard.

3. Material efficiency – reducing the material input to deliver a given product. 

“Clean electricity and low-carbon fuels are essential to decarbonise steel, cement, plastics & chemicals, aluminium, aviation and shipping – and while they carry modest “green premiums”, these are manageable at consumer level. Improving energy productivity by using materials more efficiently and deploying better technologies, enables us to meet rising demand for buildings, products and transport while reducing energy demand and related costs,” said Adair Turner, Co-Chair of the Energy Transitions Commission.

“The energy crisis provoked by the conflict in the Middle East is a reminder of how exposed many economies still are to fossil energy supply disruptions and price spikes that feed through into everything from transport and industry to food production. The shift to clean industrial supply chains, anchored to a much greater extent in domestically produced energy, chemicals, and materials (including recycled materials), is essential to make economies more resilient. And using these resources more effectively will make the transition cheaper and faster.“ said Faustine Delasalle, CEO of Mission Possible Partnership.

The opportunity is substantial. Recycling aluminium is approximately 95% less energy-intensive than new production. In cement, reducing clinker content and optimising building design represent the largest levers to lower energy requirements.

Decarbonising some energy-intensive sectors requires a transition to low-carbon solutions, such as hydrogen, ammonia, bioresources, and carbon capture and storage (CCS). These low-carbon solutions are themselves energy intensive and depend on a scaling up of clean energy infrastructure. As industries adopt low-carbon solutions, productivity improvements can limit cost increases to materials and transport, and reduce the impact on businesses and consumers.

The Energy Transitions Commission and Mission Possible Partnership’s work is anchored in four priorities that define this decisive decade: Doubling the rate of energy efficiency improvement to 4% per year by 2030; Tripling global renewable power capacity by 2030; Electrify – scaling clean electrification of growing energy demand; and Build Clean Now, moving clean industrial capacity from ambition to execution. Energy productivity improvements align with all four priorities.

Download the technical briefing: https://www.energy-transitions.org/publications/energy-productivity-for-industrial-competitiveness

About Mission Possible Partnership

Mission Possible Partnership (MPP) is an independent non-profit organisation advancing global clean industry transformation. Since 2019, we have been working with some of the most energy-intensive industries – aluminium, aviation, cement, chemicals, shipping and steel – to cut their global green house gas emissions. We mobilise business, finance, government and civil society leaders to speed up the shift to clean materials, chemicals and fuels. Having chartered sectoral pathways to net-zero, we continue to forge new territory, lifting barriers to enable a critical mass of clean industrial projects to break ground by 2030. Mission Possible Partnership has people and partners on the ground in North America, Brazil, Europe, the Middle East, North Africa, India and Asia Pacific.

For further information, visit: www.missionpossiblepartnership.org

About the Energy Transitions Commission
The Energy Transitions Commission (ETC) is a global coalition of leaders from across the energy landscape committed to achieving net-zero emissions by mid-century while supporting economic growth and development. Our Commissioners come from a range of organisations – energy producers, energy-intensive industries, technology providers, finance players and environmental NGOs. This diversity of viewpoints informs our work. This report constitutes a collective view of the ETC; however, it should not be taken as members agreeing with every finding or recommendation. The ETC is hosted by SYSTEMIQ Ltd.

For further information, visit: https://www.energy-transitions.org

Logo – https://mma.prnewswire.com/media/2954830/MPP.jpg
Logo – https://mma.prnewswire.com/media/1275002/5912504/Energy_Transitions_Commission.jpg

• Allianz Partners launches a long-term collaboration with five exceptional Para athletes as part of its “Connecting with Champions” program.
• The initiative reflects Allianz’s commitment to inclusivity, community, and the transformative power of sports.
• Employees and the Allianz Partners Board Members will actively support the athletes on their journey to the LA28 Paralympic Games.

PARIS and MUNICH, April 15, 2026 /PRNewswire/ — Allianz Partners is proud to announce a multi-year partnership with five Para athletes from four different countries:

• Bailey Moody, a wheelchair basketball player from the USA. She won one Silver medal at the Paris 2024 Paralympic Games and one Bronze medal in the Tokyo 2020 Paralympic Games.
• Jaydin Blackwell, a Para track & field athlete from the USA. He won two Gold medals at the Paris 2024 Paralympic Games and was selected 2025 USA Track & Field Men´s Para athlete of the Year.
• Jamieson Leeson, a wheelchair boccia player from Australia. She won one Silver medal at the Paris 2024 Paralympic Games.
• Josia Topf, a para swimmer from Germany. He won one Gold, one Silver and one Bronze medal at the Paris 2024 Paralympic Games and was selected Para athlete of the year 2025 in Germany.
• Ksénia Chasteau, a wheelchair tennis player from France and ranked #7 in the International Tennis Federation (ITF) Singles World Ranking.

These remarkable individuals were chosen following a global employee voting process in 2025, which engaged Allianz Partners employees worldwide in selecting athletes who embody resilience, determination, and excellence.

Tomas Kunzmann, Chief Executive Officer of Allianz Partners, states: “At Allianz Partners, we believe in the power of sports to unite and inspire. We are proud to support these five exceptional Para athletes as their authenticity, resilience and excellence in execution mirror our culture and ambitions. Together, we believe in the strength of community and our aim is to support the athletes’ journeys while fostering meaningful connections between our employees, partners, customers, and the athletes themselves.”

Jean-Marc Pailhol, Connecting with Champions program sponsor, adds: “We are committed to providing the athletes with comprehensive support from the Allianz Partners community, which includes its employees and Board Members. Our ambition is that this program raises awareness for our athletes and creates a unique connection between the Allianz family and these inspiring champions. We look forward to seeing them succeed at the LA28 Games.”

Chris McHugh, Chief Executive Officer of Allianz Partners Australia, says:
“Para athletes embody focus, discipline, and resilience – qualities that deeply resonate with us at Allianz Partners Australia. These traits reflect the way our teams strive to support customers during critical moments, often when things don’t go as planned. It’s this shared commitment to perseverance and excellence that makes us proud to be part of this campaign.”

This collaboration builds on Allianz’s long-standing partnership with the Paralympic Movement, which celebrates its 20th year anniversary in 2026. This initial engagement led to a strategic relationship, evolving to Allianz becoming Worldwide Olympic & Paralympic Partner in 2021, which will continue through 2032. As the Official Insurer of the LA28 Paralympic Games, Allianz is dedicated to empowering athletes and fans worldwide, transcending social and cultural barriers through the unifying power of sports.

Stay tuned for more updates on the “Connecting with Champions” program and the incredible journeys of these five Para athletes via the Allianz Partners Social Media channels.

About Allianz Partners

Allianz Partners is a world leader in B2B2C insurance and assistance, offering global solutions that span international health and life, travel insurance, mobility and assistance. Customer driven, our innovative experts are redefining insurance services by delivering future-ready, high-tech high-touch products and solutions that go beyond traditional insurance. Our products are embedded seamlessly into our partners’ businesses, sold through intermediary channels or directly to customers through the Allianz brand. Present in over 73 markets, our 22,600 employees speak 70 languages, handle over 95 million cases each year, and are motivated to go the extra mile to offer peace of mind to our customers around the world.  

For more information, please visit: http://www.allianz-partners.com

Social media

Follow us on X @AllianzPartners
Follow us on LinkedIn Allianz Partners
Follow us on Youtube /allianzpartners
Follow us on Instagram @allianzpartners

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial^[1], marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive form of brain cancer.

The patient was dosed at Austin Health in Melbourne, Australia, under the supervision of Professor Hui Gan. IPAX BrIGHT is assessing the safety and efficacy of TLX101-Tx in combination with chemotherapy (lomustine), compared to chemotherapy alone. The global, multicenter, open-label study will enroll patients with radiographically confirmed recurrent glioblastoma at first recurrence.

Telix’s commitment to advancing care for patients with glioblastoma is driven by the significant unmet need in this space. In the past 25 years, only two drugs have been approved by the United States Food and Drug Administration (FDA) for glioblastoma^[2], and no standard treatment currently exists for recurrent disease. Patients therefore face limited treatment options after initial therapy. TLX101-Tx offers a novel approach by targeting the L-type amino acid transporter 1 (LAT1), a transporter that enables the radiopharmaceutical to cross the blood-brain barrier and delivers therapy directly to the tumor.

IPAX BrIGHT expands upon promising data from earlier trials in the recurrent glioblastoma setting, including IPAX-1^[3], which reported a median overall survival (OS) of 13 months from the initiation of treatment with TLX101-Tx, or 23 months from initial diagnosis^[4]. Preliminary results from the IPAX-Linz investigator-initiated trial of TLX101-Tx were consistent and confirmatory to IPAX-1, with a median OS of 12.4 months from initiation of treatment and 32.2 months from initial diagnosis^[5]. Beyond the clinical trial setting, an early access program for TLX101-Tx in Europe has dosed 18 patients at first recurrence or later, further establishing the clinical utility of TLX101-Tx.

Professor Gan, Director of Cancer Clinical Trials at Austin Health, said, “Based on the prior safety profile and early efficacy data for TLX101-Tx in the IPAX-1 and IPAX-Linz studies, I am pleased to continue to explore this therapeutic modality in the first radiopharmaceutical pivotal trial in recurrent glioblastoma, where there are currently few effective treatment options.”

Dr. David N. Cade, Group Chief Medical Officer, Telix, added, “Through the IPAX BrIGHT trial, we aim to offer a new option for patients affected by glioblastoma. This registration-enabling study represents a major step forward in our mission to improve therapeutic options in neuro-oncology. With very limited innovation in treatment in recent decades, TLX101-Tx has the potential to become a first-in-class therapy that meaningfully improves patient outcomes.”

The IPAX BrIGHT study has received regulatory approval in Australia, Austria, Belgium and the Netherlands with approval being sought in additional jurisdictions. Telix’s investigational PET^[6] imaging agent for glioma, TLX101-Px (floretyrosine F 18) will be used for patient selection in IPAX BrIGHT, as well as assessing metabolic tumor response according to PET RANO 1.0^[7].

About TLX101-Tx

TLX101-Tx (¹³¹I-iodofalan) is a systemically administered radiopharmaceutical therapy that targets L-type amino acid transporter 1 (LAT1), which is typically over-expressed in glioblastoma. TLX101-Tx utilizes a small molecule approach due to the need to cross the blood brain barrier, the normal protective barrier that prevents many potential drug candidates entering the brain. In addition to the IPAX-1 and IPAX-Linz studies, TLX101-Tx is also under investigation in the IPAX-2 Phase 1 study in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma^[8]. TLX101-Tx has received orphan drug designation in the U.S. and Europe for the treatment of glioma. TLX101-Tx and TLX101-Px have not received a marketing authorization in any jurisdiction.

About glioblastoma  

Glioblastoma (GBM), is a high-grade glioma and the most common and aggressive form of primary brain cancer, with approximately 22,000 new cases diagnosed annually in the U.S.^[9]. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients^[10], with an expected survival duration of 12-15 months from diagnosis^[11].

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

MELBOURNE, Australia and Indianapolis, April 15, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (“Telix“) is pleased to announce that it has successfully priced and upsized its 1.50 per cent convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the “Issuer“), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. from US$550 million to US$600 million due to strong demand (the “Offering“). The convertible notes, also referred to as “convertible bonds” (“Convertible Bonds“), are convertible into fully paid ordinary shares in Telix (“Ordinary Shares“). The Offering received strong support from eligible investors globally.

The initial conversion price of the Convertible Bonds is US$13.85 (~A$19.55) per Ordinary Share, which represents a conversion premium of 37.5 per cent over the reference share price (A$14.22 per Ordinary Share), subject to anti-dilution adjustments set out in the final terms and conditions of the Convertible Bonds.

The Convertible Bonds will bear interest at a rate of 1.50 per cent per annum. Interest will be payable quarterly in arrear on 22 January, 22 April, 22 July and 22 October in each year, beginning on 22 July 2026. The Convertible Bonds will mature on or about 22 April 2031, unless redeemed, repurchased, or converted in accordance with their terms.

Under the reverse bookbuilding process announced by Telix on 14 April 2026 (the “Concurrent Repurchase“), Telix will concurrently repurchase approximately A$637 million of its existing A$650 million convertible bonds due 2029 (“Existing Convertible Bonds“). The Concurrent Repurchase will result in the repurchase and cancellation of more than 85% of the Existing Convertible Bonds. Telix intends to exercise its right to redeem the remaining Existing Convertible Bonds.

Settlement of the Offering and the Concurrent Repurchase is expected on 22 April 2026 and is subject to satisfaction of customary conditions. The Existing Convertible Bonds that are to be repurchased will be cancelled in accordance with their terms and conditions.

Managing Director and Group CEO, Dr. Christian Behrenbruch, said: “The successful completion of the convertible bonds refinance is in line with our capital management strategy and provides financial flexibility for Telix. We are pleased with the support we have received from both existing and new investors as part of the concurrent repurchase and new issue of convertible bonds.” 

J.P. Morgan Securities plc (“J.P. Morgan“) is Sole Bookrunner on the Offering and Sole Dealer Manager on the Concurrent Repurchase.

J.P. Morgan completed the delta placement of Ordinary Shares at a clearing price of A$14.22 per Ordinary Share, which represents an 8.0 per cent discount to Telix’s closing price of A$15.45 on 14 April 2026 and a 3.2 per cent discount to the 5-day volume weighted average price per share of A$14.69. This acts as the reference price to determine the initial conversion price of the Convertible Bonds.

Key terms of the Convertible Bonds

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.  

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. 

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including Australia, Singapore, and the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. 

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. 

Neither this announcement nor any copy hereof may be taken into or distributed in the United States. 

The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. The Convertible Bonds, the guarantees and the Ordinary Shares to be issued upon conversion of the Convertible Bonds have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act“) or the securities laws of any state or other jurisdiction of the United States and they may not be offered or sold, resold, transferred or delivered, directly or indirectly, within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. The Convertible Bonds and the guarantees are being offered and sold solely outside the United States in an “offshore transaction” as defined in, and in reliance on Regulation S under the Securities Act. 

Nothing in this announcement or anything attached to it shall form the basis of any contract or commitment. 

The Concurrent Repurchase is not being made and will not be made, directly or indirectly, in or into the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Existing Convertible Bonds may not be tendered in the Concurrent Repurchase by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States as defined in Regulation S of the Securities Act. Any purported tender of Existing Convertible Bonds made by a person located in the United States will not be accepted. 

This communication may not be distributed to the press or other media or forwarded, photocopied, passed on or, in any other manner, transmitted to any other person. Non-compliance with the foregoing may constitute a violation of law. This information is subject to change. 

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. 

All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. 

©2026 Telix Pharmaceuticals Limited. All rights reserved.